ZNF217 and breast carcinoma: Irrespective of cancer types, abnormal ZNF217 immunoreactivity was an indicator of worse 3-year (Breast cancer: P = 0.005) (Others types: P = 0.02) and 5-year prognosis respectively (Breast cancer: P = 0.01) (Others types: P = 0.0004) (Supplementary Figure S5).